Filing Overview
Registrant: Nukkleus Inc. (the request identifies T3 Defense Inc., but the filing names Nukkleus Inc.) The Form 8-K reports events beginning May 28, 2024, and was signed June 3, 2024. Nukkleus’s common stock and warrants trade on Nasdaq under NUKK and NUKKW.
Material Agreement and Financial Impact
- Nukkleus entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation (SCC) to resolve outstanding claims.
- SCC agreed to purchase designated vendor payables totaling $1,118,953.75 and exchange those payables for a settlement amount payable in Nukkleus common shares.
- The Settlement Shares will be priced at 70% of the average of the three lowest trading prices during the five-trading-day period before a share request, subject to a minimum price of $0.05 per share.
- The settlement is expected to reduce the covered payables but may result in substantial equity dilution. The filing does not provide the final number of shares to be issued.
Terms, Restrictions, and Approval
- If Nukkleus’s market price declines to or below $0.75 per share, either Nukkleus or SCC may declare a default.
- SCC may not become the beneficial owner of more than 4.99% of Nukkleus’s common stock at any time.
- Settlement Shares may not exceed 19.9% of the outstanding common stock as of May 23, 2024.
- The Circuit Court of the Twelfth Judicial Circuit Court for Manatee County, Florida approved the Settlement Agreement and share issuance on May 29, 2024, after finding the terms and conditions fair.
- The shares are intended to be issued under the Section 3(a)(10) exemption from Securities Act registration.
Outlook, Risks, and Unusual Items
- The transaction addresses outstanding vendor-related payables and claims but creates potential dilution to existing shareholders.
- The share-price-based pricing formula may increase the number of shares required to satisfy the settlement if Nukkleus’s stock price declines, subject to the stated ownership and issuance caps.
- A market price at or below $0.75 per share could trigger a contractual default.
- The filing provides no revenue, profit, cash-flow, margin, debt, cash-balance, liquidity, or forward-guidance figures.
Investor Verification Items
- Confirm the final number of Settlement Shares issued and the effective per-share settlement price.
- Assess the resulting percentage dilution against the 19.9% issuance limit and the 4.99% beneficial-ownership cap.
- Verify which vendor payables and claims are extinguished by the transaction and whether any obligations remain.
- Review the filed Settlement Agreement, court order, and subsequent SEC filings for defaults, additional share requests, or changes to the settlement.
- Reconcile the company identity: the supplied request references T3 Defense Inc., while the Form 8-K identifies Nukkleus Inc.